Sotagliflozin SGLT1/2i: A Transparent Living Meta-Analysis v13

Abstract

Patients with type 2 diabetes or recent worsening heart failure remain at high cardiovascular risk; does the use of Sotagliflozin across both settings help to reduce this? This living meta-analysis included 11,806 participants from the randomized placebo-controlled SCORED and SOLOIST-WHF trials. Hazard ratios were combined using inverse-variance fixed-effect modelling on the logarithmic scale. The pooled estimate for the primary cardiovascular composite outcome was 0.72 (95% CI 0.63–0.82) without observed heterogeneity (I² = 0%). Both trials individually supported Sotagliflozin, with SCORED reporting a hazard ratio of 0.74 and SOLOIST-WHF reporting 0.67. These findings suggest that Sotagliflozin lowers cardiovascular event risk by nearly twenty-eight percent in chronic diabetes and recently decompensated heart failure populations. Interpretation should consider possible variation during post-discharge treatment periods, the early termination of SOLOIST-WHF as well as the need for continued surveillance of ketoacidosis ri